Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy + S-1 + nimotuzumab in elderly esophageal cancer
ChiCTR2500110571Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur and nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Overall survival. Started Oct 2025; status: completed.
02
Drugs
tegafurnimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500110571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110571.